Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.
Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.
The combination was also associated with improvements in progression-free and overall survival.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.
Risk-stratification technology is evolving in chronic lymphocytic leukemia and can be used to guide treatment decisions and direct patients to clinical trials.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Most patients with previously untreated CLL experienced a persistent MRD benefit with a fixed-dose, obinutuzumab-ibrutinib–based treatment approach.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.